Article

Predicting functional residues in Plasmodium falciparum plasmepsins by combining sequence and structural analysis with molecular dynamics simulations.

Facultad de Biología, Centro de Estudios de Proteínas (CEP), Universidad de La Habana, Cuba.
Proteins Structure Function and Bioinformatics (Impact Factor: 3.34). 05/2008; 73(2):440-57. DOI: 10.1002/prot.22068
Source: PubMed

ABSTRACT Plasmepsins are aspartic proteases involved in the initial steps of the hemoglobin degradation pathway, a critical stage in the Plasmodium falciparum life cycle during human infection. Thus, they are attractive targets for novel therapeutic compounds to treat malaria, which remains one of the world's biggest health problems. The three-dimensional structures available for P. falciparum plasmepsins II and IV make structure-based drug design of antimalarial compounds that focus on inhibiting plasmepsins possible. However, the structural flexibility of the plasmepsin active site cavity combined with insufficient knowledge of the functional residues and of those determining the specificity of parasitic enzymes is a drawback when designing specific inhibitors. In this study, we have combined a sequence and structural analysis with molecular dynamics simulations to predict the functional residues in P. falciparum plasmepsins. The careful analysis of X-ray structures and 3D models carried out here suggests that residues Y17, V105, T108, L191, L242, Q275, and T298 are important for plasmepsin function. These seven amino acids are conserved across the malarial strains but not in human aspartic proteases. Residues V105 and T108 are localized in a flap of an interior pocket and they only establish contacts with a specific non-peptide achiral inhibitor. We also observed a rapid conformational change in the L3 region of plasmepsins that closes the active site of the enzyme, which explains earlier experimental findings. These results shed light on the role of V105 and T108 residues in plasmepsin specificities, and they should be useful in structure-based design of novel, selective inhibitors that may serve as antimalarial drugs.

0 Bookmarks
 · 
184 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hemoglobin degradation pathway is the major source of nutrition of Plasmodium falciparum. Plasmepsin II is the key enzyme in hemoglobin degradation with two catalytic aspartates D34 and D214. The energy refined structure of Plasmepsin II of Plasmodium falciparum modeled by modeller 9v8 using PDB entry 1PFZ as template. Ligsitecsc program revealed three potential ligand binding sites where the pkt-364 is found to be more favorable containing critical aspartic residues (D34 and D214). Urea and its derivative, benzamide, are considered as seed molecules for de-novo generation of structurally complimentary lead molecules. LigbuilderV1.2 growing strategy was used for de-novo generation with 10 population cycles for each seed molecules. Binding energies were examined by Quantum3.3.0 for all the designed ligand molecules and the best molecules with -20KJ/mole and -18KJ/mole were found with some undesired activities. Iterative in-silico optimization of the examined molecules were done and finally de-novo generated N - [ (R) – hydroxy { [ 2 - ( 1 , 3 – oxathiol – 4 –yl ) phenyl ] amino } methyl ] acetamide and N - ( 2 – amino – 2 – oxoethyl ) – 3 - ( 1 - { [ 2 - ( methylamino ) ethyl ] (phenyl) amino } vinyl ) benzamide were found as the best fit over rule of 5 and other ADME parameters. Binding studies suggest the direct interaction of designed molecules with catalytic aspartates (D34 and D214) of Plasmepsin II having 2HB and 1 ionic bond and good number of VdW interactions. Thus, the designed molecules could possibly inhibit the action of PM II preventing the degradation of hemoglobin and thereby kill the parasite by starvation.
    International Journal of ChemTech Research 01/2011; 3(3):1538-1547.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The drugs against tropical neglected diseases, especially Chagas' Disease, were launched more than 30 years ago, and the development of resistance requires the discovery of new and more effective chemotherapeutic agents. Trypanosoma cruzi has a redox enzyme called trypanothione reductase which was successfully inhibited for peptide derivatives (McKie et al., Amino Acids, 2001, 20: 145). This work aims at studying the mechanism of inhibition of this enzyme through molecular dynamics simulations and evaluating the behavior of some derivatives when inhibiting this protein. We should affirm that any particular molecular dynamics analysis tools (Hbond pattern, 3-D root-mean-square deviation, solvent accessible surface area, etc.) cannot be used apart from the others to justify completely these peptides inhibitory patterns. Based on our results, we reproduced the experimental data and, moreover, we discriminated against a new site in enzyme aperture, which can assist the development of powerful inhibitors against trypanothione reductase enzyme.
    Chemical Biology &amp Drug Design 06/2012; 80(4):561-71. · 2.47 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Over the last decades, a vast structural knowledge has been gathered on the HIV-1 protease (PR). Noticeably, most of the studies focused the B-subtype, which has the highest prevalence in developed countries. Accordingly, currently available anti-HIV drugs target this subtype, with considerable benefits for the corresponding patients. However, in developing countries, there is a wide variety of HIV-1 subtypes carrying PR polymorphisms related to reduced drug susceptibility. The non-active site mutation, M36I, is the most frequent polymorphism, and is considered as a non-B subtype marker. Yet, the structural impact of this substitution on the PR structure and on the interaction with natural substrates remains poorly documented. Results Herein, we used molecular dynamics simulations to investigate the role of this polymorphism on the interaction of PR with six of its natural cleavage-sites substrates. Free energy analyses by MMPB/SA calculations showed an affinity decrease of M36I-PR for the majority of its substrates. The only exceptions were the RT-RH, with equivalent affinity, and the RH-IN, for which an increased affinity was found. Furthermore, molecular simulations suggest that, unlike other peptides, RH-IN induced larger structural fluctuations in the wild-type enzyme than in the M36I variant. Conclusions With multiple approaches and analyses we identified structural and dynamical determinants associated with the changes found in the binding affinity of the M36I variant. This mutation influences the flexibility of both PR and its complexed substrate. The observed impact of M36I, suggest that combination with other non-B subtype polymorphisms, could lead to major effects on the interaction with the 12 known cleavage sites, which should impact the virion maturation.
    BMC Genomics 10/2014; 15(S7):S5. · 4.40 Impact Factor

Full-text (3 Sources)

Download
104 Downloads
Available from
May 19, 2014